End-to-End Platform for Human Pluripotent Stem Cell Manufacturing

Area of Science:

• Regenerative Medicine
• Biotechnology
• Cell Therapy Manufacturing

Background:

• Industrializing stem cell therapies requires scalable production platforms.
• Human pluripotent stem cells (hPSCs) are crucial for generating therapeutic cells.
• Current methods face challenges in scaling production and maintaining quality.

Purpose of the Study:

• To develop and validate a closed, automated, and scalable bioreactor platform for hPSC expansion.
• To ensure high-quality, consistent hPSC production for clinical and commercial applications.
• To reduce labor and contamination risks in stem cell manufacturing.

Main Methods:

• Utilized a stirred tank bioreactor system for perfused, xeno-free expansion of hPSCs.
• Implemented closed-step procedures for cell harvest, concentration, and cryopreservation.
• Assessed hPSC quality through marker expression, karyotype analysis, and differentiation potential.

Main Results:

• Achieved high fold expansion of hPSCs in the automated bioreactor system.
• Demonstrated maintenance of hPSC-specific markers and normal karyotype post-expansion.
• Confirmed the ability of expanded hPSCs to differentiate into multiple cell types.
• Successfully cryopreserved and thawed hPSCs for subsequent expansion or differentiation.

Conclusions:

• The developed end-to-end platform supports large-scale expansion of high-quality hPSCs.
• This scalable solution can meet the cell demand for various clinical indications.
• The automated, closed system enhances efficiency and safety in cell therapy manufacturing.